Blood test may outsmart PET scans in childhood cancer

NCT ID NCT07356882

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a simple blood test (called a liquid biopsy) can better predict relapse in children and young adults with classical Hodgkin lymphoma. Researchers will track 400 patients under 25 to see if tumor DNA in the blood can catch early signs of relapse or treatment failure. The goal is to improve risk assessment and tailor treatments more precisely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test that helps doctors personalize treatment for young Hodgkin lymphoma patients, catching relapses earlier and reducing unnecessary side effects.
What could go wrong: This is an observational study, not a treatment trial. The blood test is still experimental and may not prove accurate enough to replace current imaging methods like PET/CT scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLASSICAL HODGKIN LYMPHOMA

Contacts and locations

Locations

Pediatric Hematology and Oncology Department
RECRUITING

Paris, 75012, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.